Microcolin H, a novel autophagy inducer, exerts potent antitumour activity by targeting PITPα/β

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Phosphatidylinositol transfer protein alpha/beta isoform (PITPα/β) is crucial for cellular lipid metabolism and phosphoinositide trafficking.
• PITPα/β's role in cancer therapy remains largely unexplored despite its cellular significance.

Purpose of the Study:

• To investigate PITPα/β as a potential therapeutic target in cancer.
• To evaluate the anti-cancer activity of microcolin H, a marine lipopeptide, against tumors.
• To elucidate the mechanism of action of microcolin H in cancer cells.

Main Methods:

• Analysis of clinical cancer samples to correlate PITPα/β expression with prognosis.
• Chemical proteomic methods for target identification.
• In vitro antiproliferative assays on various tumor cell lines.
• Western blot analysis to assess autophagy markers (LC3I/II, p62).
• In vivo anti-tumor efficacy studies in mouse models.

Main Results:

• Elevated PITPα/β expression is linked to poor prognosis in cancer patients.
• Microcolin H directly binds to PITPα/β and exhibits significant anti-proliferative effects.
• Microcolin H induces autophagic cell death by promoting LC3I to LC3II conversion and reducing p62 levels.
• Microcolin H demonstrates potent anti-tumor efficacy with low toxicity in vivo.

Conclusions:

• PITPα/β is a viable therapeutic target for cancer treatment.
• Microcolin H, by targeting PITPα/β, effectively induces autophagic cell death and inhibits tumor growth.
• This study highlights a novel therapeutic strategy for cancer leveraging microcolin H and PITPα/β inhibition.